Midday Report: Viracta (VIRX) Falls on June 22

Equities Staff  |

Viracta Therapeutics Inc (NASDAQ: VIRX) has dropped $0.19 (7.12%) and is currently sitting at $2.55, as of 12:14:18 est on June 22.

624,439 shares exchanged hands.

The Company is up 11.25% over the last 5 days and shares advanced 26.54% over the last 30 days.

Viracta is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Viracta visit the company profile.

About Viracta Therapeutics Inc

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

To get more information on Viracta Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Viracta Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content